Aroa Biosurgery Limited
ARX.AX
Australian Securities Exchange0.68
AUD
- -
- -
Aroa Biosurgery Limited
ARX.AX
(Australian Securities Exchange)
Recent
price
0.68
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Aroa Biosurgery Limited is an innovative regenerative medicine company dedicated to developing, producing, and marketing advanced medical devices for intricate wound care and soft tissue reconstruction globally. Founded in 2008 and based in Auckland, New Zealand, with a U.S. presence in San Diego, California, the company is publicly traded on the Australian Securities Exchange under the ticker ARX. The firm's core offerings are built upon its unique proprietary ovine forestomach matrix (AROA ECM™) technology, a sophisticated extracellular matrix biomaterial derived from sheep tissue. This platform serves as a natural scaffold, encouraging the body's own cells to regenerate and foster healing. Aroa Biosurgery’s product portfolio includes solutions like Endoform® Natural and Endoform® Antimicrobial for managing acute and chronic wounds, alongside Myriad Matrix™, Myriad Morcells™, and Myriad Morcells Fine™, which are engineered for soft tissue repair, reinforcement, and complex wound applications. Additionally, the company provides Symphony™ for severe wound closure and Reinforced Bioscaffolds, utilized in surgical procedures such as ventral hernia repair and abdominal wall reconstruction. Aroa also received FDA clearance for a new resorbable dental barrier in early 2024. Aroa Biosurgery generates revenue primarily through the sale of its medical and surgical devices, with a significant market presence in the United States, as well as expansion into Canada, Europe, and select Asian countries. Recent highlights include continued growth in Myriad product sales, an expanding U.S. sales team, and the advancement of its Enivo™ system for surgical dead space management, which completed its first clinical pilot study in 2024. A notable partnership was established in September 2024 with HCAH to launch a wound care initiative in India, introducing new product lines for complex vascular and diabetic wounds. The company emphasizes making high-quality, effective, and accessible products that improve patient outcomes.
Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.